New drug combo shows promise for rare blood cancer
NCT ID NCT02737046
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tested a drug called belinostat combined with zidovudine (AZT) as a follow-up treatment for people with adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. The goal was to see if this combination could clear cancer cells from the blood and keep the disease under control. Fifteen participants were enrolled, and researchers measured how many achieved a complete molecular response (no detectable cancer cells) and monitored side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.